Eli Lilly’s lauded discount of its obesity drug Zepbound comes with caveats
Eli Lilly garnered widespread praise Tuesday for launching discounted versions of its blockbuster obesity drug Zepbound. Before, the treatment had only been sold in injectable pens for a list price of $1,060 per month, but now, Lilly will also sell starter doses in vials that cost up to $549 a month, “expanding supply and access,” the company said.
In Lilly’s press release, one patient group called it “an innovative solution that brings us closer to making equitable care a reality.” And even President Biden chimed in on X, crediting his administration’s work on pressuring drugmakers to lower prices.
Read Original Article: Eli Lilly’s lauded discount of its obesity drug Zepbound comes with caveats »
